Fominoben

Fominoben
Clinical data
Trade namesBroncomenal, Deronyl, Finaten, Noleptan, Oleptan, Terion, Tosifar, Tussirama
Identifiers
  • N-[3-chloro-2-[[methyl-(2-morpholin-4-yl-2-oxoethyl)amino]methyl]phenyl]benzamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.038.135 Edit this at Wikidata
Chemical and physical data
FormulaC21H24ClN3O3
Molar mass401.89 g·mol−1
3D model (JSmol)
  • CN(CC1=C(C=CC=C1Cl)NC(=O)C2=CC=CC=C2)CC(=O)N3CCOCC3
  • InChI=1S/C21H24ClN3O3/c1-24(15-20(26)25-10-12-28-13-11-25)14-17-18(22)8-5-9-19(17)23-21(27)16-6-3-2-4-7-16/h2-9H,10-15H2,1H3,(H,23,27)
  • Key:KSNNEUZOAFRTDS-UHFFFAOYSA-N

Fominoben is an antitussive agent of the benzanilide class, formerly marketed under the name Noleptan. It binds poorly to the sigma-1 receptor, a receptor activated by many other antitussives. It is reported to have respiratory stimulant activity. Other research has indicated it may be an agonist at the benzodiazepine site of the GABAA receptor. It was introduced in Germany in 1973, in Italy in 1979, and in Japan in 1983.

Adverse effects include appetite suppression, nausea, vomiting, insomnia, irritability, and hallucinations. Rarer side effects include somnolence, dizziness, dry mouth, blurred vision, and urticaria.